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  Introduction 
HIV infection predisposes a person to fungal infections because of 
failure in the host's cell-mediated immunity, which may result in 
a variety of fungal infections (1,2). Candidiasis is commonly caused 
by Candida albicans which can become a multi-system problem affecting 
the patient's nails, mouth, oesophagus, lower gastrointestinal tract, 
genitalia and rectum. Candida oesophagitis is a condition diagnostic 
of AIDS and characterised by erythematous lesions, pseudomembranous 
areas and/or ulcerations of the oesophagus. The condition may cause 
difficulty in swallowing, retrosternal pain, nausea and vomiting. 
Significant weight loss may also develop secondary to the characteristic 
symptoms of oesophageal candidiasis (3). 
 
Reports to date suggest therapy failure, incomplete response and 
decreasing susceptibility to azole medications such as ketoconazole, 
fluconazole and itraconazole (4). Whilst amphotericin remains the 
standard treatment for systemic or resistant mycoses (1), hospital 
experience with amphotericin toxicity may be a limiting factor against 
initiating homebased therapy (1).  
 
We report the outcomes for a clinically responding patient with a 
falling CD4 count diagnosed with oesophageal candidiasis receiving 
intravenous amphotericin at home for a continuous seventeen month 
period. This case fulfils current definitions of long-term survival 
(5,6).  
 
The patient initially presented over three years previously with 
HIV-related thrombocytopenia, a diagnosis made after counselling and 
HIV antibody testing showed HIV infection.  
 
Over successive years the patient received out-patient follow up 
including quarterly CD4 monitoring, treatment with Zidovudine, 
prophylaxis with Cotrimoxazole against Pneumocystis carinii pneumonia, 
psychological counselling, oral and dental, care and social welfare 
interventions. The out-patient service included written information 
for the patient's General Medical Practitioner after each out-patient 
visit, on patient request. 
 
On presentation with oesophageal candidiasis due to Candida albicans 
three years later, the patient requested homebased care in association 
with the General Medical Practitioner (GP) and the rest of the primary 
healthcare team. The patient wished to keep hospital stays and 
out-patient visits to a minimum. 
 
The blood results for the patient's serum creatinine, urea and potassium 
are shown in Figures 1-3, respectively, for a total period of seventeen 
months during which amphotericin was administered. The data covers 
both the two week period of hospital based induction therapy and the 
following seventeen months of homebased maintenance therapy. 
 
 Treatment Protocol 
Amphotericin induction therapy was administered in hospital over the 
fourteen day period, following incomplete clinical response to oral 
azole therapy with ketoconazole, fluconazole, and itraconazole, 
respectively. No significant side-effects after induction therapy 
were observed and indwelling central venous access was achieved before 
discharge with the Port-a-Cath system available from Kabi Pharmacia 
Ltd. 
 
On discharge home, the patient was prescribed an alternating regime 
of twice and thrice weekly maintenance doses of intravenous amphotericin 
50mg. The drug was reconstituted in 5% dextrose (7) and was continuously 
self-administered over a period of seventeen months.   
 
Each dose of GP prescribed amphotericin was aseptically prepared, 
loaded into the Intermate system, a portable, non-gravity dependent 
self-infusion device (Figure 4) and delivered to the patient's home, 
by Caremark Ltd. The patient was able to self-administer the doses 
with Intermate, which is currently prescribed for homebased therapy 
in cystic fibrosis and haemoglobinopathies to give antibiotic and 
iron chelation therapy (8,9), respectively.  
 
The treatment protocol comprises twice weekly venepuncture by the 
practice nurse working to serum parameters which were set through 
dialogue between the General Medical Practitioner, the Consultant 
Haematologist and supported through the liaison practice of the Clinical 
Nurse Specialist. 
 Model Of Care 
The need for "shared care" for HIV patients has already been addressed 
in United Kingdom especially for patients with Cytomegalovirus retinitis 
requiring homebased Foscarnet and/or Ganciclovir (10,11). Shared care 
is novel and variable within the United Kingdom (12), even though 
some regions have already developed extensive homebased schemes. 
However, the community focus of such developments maybe more commonly 
associated with other country's healthcare systems (13). 
 
Generally, the communication systems which exist spanning acute and 
primary healthcare to service such "shared care" schemes in the United 
Kingdom, are poorly developed. General Medical Practitioners may have 
limited access to the available hospital based expertise (12,14).  
 To sustain such a model of care, close liaison and sharing of information 
between hospital and community services is essential to facilitate 
and improve the choices for homebased therapy. This requires both 
the liaison work of specialist nurses/Clinical Nurse Specialists (CNS's) 
to link both the hospital and community services (15,16), as well 
as regular written and verbal communication between hospital and 
community physicians. 
 
Prescribing and clinical responsibility lies with the GP who works 
in close liaison and collaboration with hospital-based specialists 
and community-based specialist and generic nurses. Costs of the 
Intermate infusion device and medication available through FP10 
prescribing were  refunded to the GP's budget after anonymous clinical 
case notification of diagnosis to the GP's own Family Health Services 
Authority's pharmaceutical advisor. 
 
 Community Nursing Care 
In the case reported, instruction in the use of the Port-a-Cath and 
Intermate systems whilst in hospital was lead through the interventions 
of the CNS, in association with the hospital nursing staff. The patient 
was instructed in non-touch technique whilst infusing through the 
Port-a-Cath, "gripper" needle insertion, flushing the system, and 
during safe connection of the Intermate system.  
 
The CNS provided the clinical resource for the community nursing staff 
in terms of education about the disease and addressing training needs. 
An important role for the specialist nurse was one of professional 
support for the community nursing staff involved in the patient's 
care.  
 
Availability of a clinical nurse specialist as a resource was facilitated 
by close links into the primary network and the quick response times 
for community nurse enquiries, much  enhanced through utilisation 
of an aircall message paging system. 
 
The practice nurse, as well as assisting with blood monitoring given 
the agreed acceptable parameters for serum creatinine, urea and 
potassium, also provided nurse counselling and practical support to 
this ambulant patient during the  twice  weekly attendances at the 
practice.  
 
The role of the practice nurse with this symptomatic patient was 
integrated into the pre-existing role of the nurse where the caseload 
already included care for other patients with terminal diagnoses. 
Focusing this patient's care back into the community helped to 
"normalise" the patient's treatment, given the patient was fully 
ambulant and was well enough to return to a manual occupation for 
the first nine months of homebased treatment, following successful 
hospital induction therapy with amphotericin.  
 
The client's self-care at home was enhanced initially on hospital 
discharge and prior to resumption of work, through the interventions 
of district nursing. District nurses within the United Kingdom work 
collaboratively and holistically with patients and the frequency of 
home visiting will vary according to individual patient's needs.  
 Care Outcomes 
The patient's request for an independent life outside of hospital 
was supported through the medical and nursing agencies of primary 
healthcare in association with the Clinical Nurse Specialist acting 
as a link between the hospital and community staff. 
 
Significant clinical response to therapy at home has been achieved 
without chills, fever and significant nausea. One documented episode 
of asymptomatic elevated serum creatinine (> 260 mmol/l) has occurred. 
The therapy was discontinued for seven days and recommenced on return 
of the serum creatinine to within less potentially toxic limits.  
 
One episode of line sepsis during the seventeen month infusion period 
with amphotericin was due to Staphylococcus epidermis and one episode 
of Candida albicans septicaemia required hospitalisation and treatment 
with amphotericin for fifteen days. On discharge home and after 
counselling from medical and nursing staff, the patient decided to 
take retirement from work on grounds of ill-health. 
 
On two occasions a trial of oral fluconazole therapy has been attempted. 
On the first occasion, intravenous amphotericin was instituted within 
ten days due to regrowth in the upper oesophagus of Candida albicans, 
with concurrent weight loss. On the second occasion, after seventeen 
months of intravenous amphotericin therapy, no regrowth appears to 
have occurred on visual observation of the upper oesophagus, with 
further endoscopy planned to substantiate these clinical findings. 
 
The specific factors facilitating homecare in this particular instance 
include the prescribing and blood monitoring role of the General Medical 
Practitioner, the involvement of a locally available Clinical Nurse 
Specialist working alongside practice and district nurses, as well 
as the clinical experience of the hospital Consultant Haematologist 
with the treatment of systemic mycoses. 
 
The patient's quality of life was maintained at a level which the 
patient felt gave substantial advantages for independent living. 
Institutional equipment such as "drip" stands and volumetric infusions, 
were thereby kept to a minimum as they may limit ambulation at home, 
are often user unfriendly which may foster dependency. Unsatisfactory 
alternatives to homecare were in-patient hospital stays or attendance 
at out-patient clinics for intravenous therapy, neither of which were 
acceptable to the patient. 
 
Also, the Intermate system allowed the patient the freedom of choice 
to self-medicate at work or home, during convenient times with 
unrestricted ambulation. The appearance of the Intermate device is 
self-effacing and handling of the complete system is a relatively 
simple procedure. Therefore, Intermate has been useful in this case, 
for integrating a  potentially difficult therapy into the patient's 
home context and lifestyle. 
  
Therefore, therapies previously considered suitable for administration 
in the hospital environment, may be self-administered with appropriate 
medical and nursing support, by patients in their own home surroundings. 
Studies have suggested that factors such as satisfaction with, and 
access to requisite services may be conducive to facilitating survival 
for people who are living with HIV disease (4). 
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